These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
65 related articles for article (PubMed ID: 9467985)
1. Understanding Discordance between In Vitro Dissolution, Local Gut and Systemic Bioequivalence of Budesonide in Healthy and Crohn's Disease Patients through PBPK Modeling. Han C; Sun T; Chirumamilla SK; Bois FY; Xu M; Rostami-Hodjegan A Pharmaceutics; 2023 Aug; 15(9):. PubMed ID: 37765205 [TBL] [Abstract][Full Text] [Related]
2. Predicting and Understanding the Human Microbiome's Impact on Pharmacology. Hitchings R; Kelly L Trends Pharmacol Sci; 2019 Jul; 40(7):495-505. PubMed ID: 31171383 [TBL] [Abstract][Full Text] [Related]
3. Organelle targeting: third level of drug targeting. Sakhrani NM; Padh H Drug Des Devel Ther; 2013; 7():585-99. PubMed ID: 23898223 [TBL] [Abstract][Full Text] [Related]
8. A safety evaluation of budesonide MMX for the treatment of ulcerative colitis. Bezzio C; Festa S; Zerboni G; Papi C; Manes G; Saibeni S Expert Opin Drug Saf; 2018 Apr; 17(4):437-444. PubMed ID: 29473429 [TBL] [Abstract][Full Text] [Related]
9. The role of Budesonide-MMX in active ulcerative colitis. Gionchetti P; Praticò C; Rizzello F; Calafiore A; Capozzi N; Campieri M; Calabrese C Expert Rev Gastroenterol Hepatol; 2014 Mar; 8(3):215-22. PubMed ID: 24502535 [TBL] [Abstract][Full Text] [Related]
10. Review article: Targeted drug delivery in treatment of intestinal diseases. Wikberg M; Ulmius J; Ragnarsson G Aliment Pharmacol Ther; 1997 Dec; 11 Suppl 3():109-15. PubMed ID: 9467985 [TBL] [Abstract][Full Text] [Related]
11. Reviewing the therapeutic role of budesonide in Crohn's disease. López-Sanromán A; Clofent J; Garcia-Planella E; Menchén L; Nos P; Rodríguez-Lago I; Domènech E Gastroenterol Hepatol; 2018; 41(7):458-471. PubMed ID: 30007787 [TBL] [Abstract][Full Text] [Related]